Tectonic Therapeutic Positive Interim Data from Phase 1b Trial for TX45 in Pulmonary Hypertension

 

• TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), supporting endpoints and patient population in ongoing APEX Phase 2 clinical trial
• Interim analysis demonstrated that TX45 achieved 17.9% reduction in Pulmonary Capillary Wedge Pressure (“PCWP”) in the total study population of PH-HFpEF and >30% reduction in Pulmonary Vascular Resistance (“PVR”) in Combined pre- and post-capillary PH (“CpcPH”), a subpopulation with more severe disease
• TX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events, significant hypotension, or immune related reactions
• Company to host conference call and webcast today at 8:00 a.m. ET

https://www.globenewswire.com/news-release/2025/01/30/3017839/0/en/Tectonic-Therapeutic-Announces-Positive-Interim-Data-from-Phase-1b-Trial-for-TX45-in-Patients-with-Group-2-Pulmonary-Hypertension-in-HFpEF.html